false
Catalog
Workshop: Stimulant Use Disorder Treatment: Update ...
Stimulant Use Disorder Treatment: Updates from the ...
Stimulant Use Disorder Treatment: Updates from the ASAM/AAAP National Practice Guideline
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The workshop centered on the newly published AAAP-ASAM clinical practice guideline for stimulant use disorder, emphasizing a comprehensive and holistic clinical management approach. The guidelines cover screening, diagnosis, behavioral and pharmacotherapy treatments, and specific populations like those with co-occurring disorders, adolescents, pregnant women, LGBTQ+ individuals, and those involved in the criminal justice system or experiencing homelessness. The utility of contingency management, a behavioral model rewarding patients for abstinence, is strongly highlighted as effective. Cognitive behavioral therapy (CBT), community reinforcement approaches, and adaptations within the matrix model are also emphasized. The workshop explored off-label pharmacotherapies for stimulant use disorders, where bupropion, mirtazapine, naltrexone-bupropion, topiramate, and methylphenidate were noted for methamphetamine use, while modafinil, topiramate, mixed amphetamine salts with topiramate, and bupropion were mentioned for cocaine use. The evidence for these pharmacotherapies is described as weak to moderate. The significant focus was placed on the necessity to monitor and manage risks when prescribing off-label controlled medications, stressing that only trained specialists should undertake such treatments. Special considerations are discussed, such as implementing integrated treatment plans for those with stimulant use disorder and co-occurring psychiatric disorders and promoting harm reduction strategies. The seminar concluded with a case discussion, emphasizing the complexity and variability in managing stimulant use disorder, highlighting individualized patient care and evidence-based strategies.
Keywords
AAAP-ASAM guideline
stimulant use disorder
Dr. Larissa Mooney
Dr. Brian Hurley
Dr. Severino
screening and assessment
contingency management
Cognitive Behavioral Therapy
Matrix Model
pharmacotherapy
co-occurring disorders
harm reduction
patient engagement
treatment adherence
AAAP-ASAM guidelines
comprehensive management
behavioral treatments
off-label pharmacotherapies
methamphetamine treatment
cocaine treatment
individualized care
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.
400 Massasoit Avenue
Suite 108
East Providence, RI 02914
cmecpd@aaap.org
Privacy
About
Advocacy
Membership
Fellowship
Education and Resources
Training Events
×
Please select your language
1
English